Search company, investor...
Search

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

suvica.com

Stage

Grant | Alive

Total Raised

$1.5M

Last Raised

$1.5M | 7 yrs ago

About SuviCA

SuviCa is focused on the discovery and development of small molecules for the treatment of cancer. Currently, SuviCa has two small molecule protein synthesis inhibitors in pre-clinical development. SVC112 – With a patent filed for Composition of Matter protection, SVC112 has shown pre-clinical efficacy as monotherapy and in combination with standard therapies such as radiation and newly approved targeted agents. SVC112 is in pre-clinical development for a variety of cancer indications, including head & neck cancer, melanoma, colorectal cancer, and non-small cell lung cancer. SVC201 – Originally identified using SuviScreen, SVC201 shows potent anti-tumor activity against a panel of human colorectal cancer cell lines. Similar to SVC112, SVC201 inhibits protein synthesis; however, its mechanism of action is distinct from that of SVC112. SVC201 is currently in lead optimization.

SuviCA Headquarters Location

PO Box 3131

Boulder, Colorado, 80307,

United States

303-921-6680

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing SuviCA

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

SuviCA is included in 2 Expert Collections, including Cancer.

C

Cancer

4,784 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

B

Biopharma Tech

838 items

SuviCA Patents

SuviCA has filed 2 patents.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

8/10/2016

4/16/2019

Experimental cancer drugs, Oncology, Protein biosynthesis, Cancer treatments, Gene expression

Grant

Application Date

8/10/2016

Grant Date

4/16/2019

Title

Related Topics

Experimental cancer drugs, Oncology, Protein biosynthesis, Cancer treatments, Gene expression

Status

Grant

SuviCA Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

SuviCA Rank

  • Where is SuviCA's headquarters?

    SuviCA's headquarters is located at PO Box 3131, Boulder.

  • What is SuviCA's latest funding round?

    SuviCA's latest funding round is Grant.

  • How much did SuviCA raise?

    SuviCA raised a total of $1.5M.

  • Who are the investors of SuviCA?

    Investors of SuviCA include National Cancer Institute.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.